Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry-Reference-Cited by-同舟云学术

Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry

Published:2012-10-11 Issue:3 Volume:112 Page:164-170
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Gong Inna Y.,Mansell Sara E.¹,Kim Richard B.

Affiliation:

1. Division of Clinical Pharmacology; University of Western Ontario; London; ON; Canada

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcpt.12005/fullpdf

Reference27 articles.

1. Triggers, targets and treatments for thrombosis;Mackman;Nature,2008

2. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism;Eriksson;Annu Rev Med,2011

3. Oral anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines;Ageno;Chest,2012

4. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development;Eriksson;Clin Pharmacokinet,2009

5. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment;Fox;Eur Heart J,2011

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between genotypes ofABCB1, ABCG2andCYP3A5and the risk of atrial fibrillation;2024-07-16

2. Common P-glycoprotein (ABCB1) polymorphisms do not seem to be associated with the risk of rivaroxaban-related bleeding events;Biochemia medica;2024-06-15

3. Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy;Clinical Pharmacokinetics;2024-03

4. Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease;Rational Pharmacotherapy in Cardiology;2023-11-07

5. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation;Human Genomics;2023-07-07